1
|
Grabar S, Potard V, Piroth L, Abgrall S, Bernard L, Allavena C, Caby F, de Truchis P, Duvivier C, Enel P, Katlama C, Khuong MA, Launay O, Matheron S, Melica G, Melliez H, Meynard JL, Pavie J, Slama L, Bregigeon S, Tattevin P, Capeau J, Costagliola D. Striking differences in weight gain after cART initiation depending on early or advanced presentation: results from the ANRS CO4 FHDH cohort. J Antimicrob Chemother 2023; 78:757-768. [PMID: 36683307 DOI: 10.1093/jac/dkad007] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Accepted: 01/03/2023] [Indexed: 01/24/2023] Open
Abstract
BACKGROUND Many studies have reported weight gain in ART-naive people living with HIV (PWH) initiating an integrase strand-transfer inhibitor-based regimen. We studied the impact of early or advanced presentation and that of individual drugs in PWH initiating combined ART (cART) between 2012 and 2018. METHODS From the French Hospital Database HIV cohort, we assessed factors associated with a weight gain ≥10%, weight change after cART initiation or BMI increase ≥5 kg/m2 up to 30 months. The analyses were conducted overall, and among PWH with early (primary infection or CD4 >350/mm3 and viral load <100 000 copies/mL, without AIDS) and advanced presentation (AIDS or CD4 <200/mm3, not during primary infection). RESULTS At 30 months, 34.5% (95% CI: 33.5-35.6) of the 12 773 PWH had a weight gain ≥10%, with 20.9% (95% CI: 19.6-22.2) among the 5794 with early presentation and 63.1% (95% CI: 60.9-65.3) among the 3106 with advanced presentation. Weight gain was 2.8 kg (95% CI: 2.0-3.7) for those with early presentation and 9.7 kg (95% CI: 8.4-11.1) for those with advanced presentation. Most weight gain occurred in the first 12 months. Underweight and obese PWH were at significantly higher risk of a BMI increase ≥5 kg/m2 than normal-weight PWH. Results differed within classes and by outcome. Raltegravir and dolutegravir were consistently associated with greater weight gain than the other third agents. Tenofovir alafenamide was also associated with higher weight gain than tenofovir disoproxil or abacavir. CONCLUSIONS After initiating cART, PWH with early presentation exhibited a small weight gain, whereas it was large among those with advanced presentation. The choice of ART should account for the risk of weight gain, especially for PWH who present with advanced disease and/or are obese.
Collapse
Affiliation(s)
- Sophie Grabar
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP, Hôpital St Antoine, F75012, Paris, France
| | - Valérie Potard
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F75013, Paris, France
| | - Lionel Piroth
- Infectious Diseases Department, CHU Dijon, and Inserm CIC 1432 Université de Bourgogne, Dijon, France
| | - Sophie Abgrall
- AP-HP, Hôpital Béclère, Service de Médecine Interne, Clamart, and Université Paris-Saclay, CESP INSERM U1018, Le Kremlin-Bicêtre, France
| | | | - Clotilde Allavena
- Infectious Diseases Department, INSERM EA1413, CHU de Nantes, Nantes, France
| | - Fabienne Caby
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F75013, Paris, France.,Unité VIH-IST, Service d'Immuno-Hematologie, Hôpital Victor Dupouy, Argenteuil, France
| | - Pierre de Truchis
- AP-HP Hôpital Raymond Poincaré, Université Paris-Saclay, Garches, France
| | - Claudine Duvivier
- AP-HP, Hôpital Necker-Enfants Malades, Service de Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur, Paris, France.,IHU Imagine, Paris, France.,Institut Cochin-CNRS 8104-INSERM U1016, Université Paris Cité, Paris, France.,Institut Pasteur, Centre Médical de l'Institut Pasteur, Paris, France
| | - Patricia Enel
- Assistance Publique-Hôpitaux de Marseille, Public Health Department, Marseille, and Aix-Marseille University, CEReSS, Health Service Research and Quality of Life Center, Marseille, France
| | - Christine Katlama
- AP-HP, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and AP-HP, Hôpital Pitié-Salpêtrière, Paris, France
| | | | - Odile Launay
- Université Paris-Cité, AP-HP, Hôpital Cochin, INSERM, CIC 1417, Paris, France
| | - Sophie Matheron
- Service de Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, GHU Paris Nord, AP-HP, Paris, France
| | - Giovanna Melica
- Clinical Immunology and Infectious Diseases Department, Henri Mondor Hospital, Creteil, France
| | - Hugues Melliez
- Médecine Interne, Hôpital Riaumont, 62 800, Liévin, France
| | - Jean-Luc Meynard
- AP-HP, Department of Infectious Diseases, Saint-Antoine Hospital, Paris, France
| | - Juliette Pavie
- Department of Immunology and Infectious Diseases, AP-HP Hôtel-Dieu, Paris, France
| | - Laurence Slama
- Infectious Diseases Unit, Hôtel Dieu Hospital, APHP, Paris, France
| | - Sylvie Bregigeon
- Aix-Marseille Université, APHM, Hôpital Sainte-Marguerite, Marseille, France
| | - Pierre Tattevin
- Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Centre Hospitalo-Universitaire, Rennes, France
| | - Jacqueline Capeau
- Sorbonne Université, INSERM UMR_S 938, Centre de Recherche Saint-Antoine (CRSA), Institute of Cardiometabolism and Nutrition (ICAN), F75012, Paris, France
| | - Dominique Costagliola
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, F75013, Paris, France
| |
Collapse
|
2
|
Melliez H, Mary-Krause M, Guiguet M, Carrieri P, Abgrall S, Enel P, Gallien S, Duval X, Duvivier C, Pavie J, Siguier M, Freire-Maresca A, Tattevin P, Costagliola D. Risk of Severe Bacterial Infection in People Living Human Immunodeficiency Virus Infection in the Combined Antiretroviral Therapy Era. J Infect Dis 2021; 222:765-776. [PMID: 32253435 DOI: 10.1093/infdis/jiaa154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Accepted: 04/01/2020] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Severe bacterial infections are the first cause of morbidity in people with human immunodeficiency virus (PWH). We aimed to assess their incidence and to analyze their determinants. METHODS We studied human immunodeficiency virus (HIV)-1-infected individuals aged at least 15 years and prospectively followed between 2006 and 2015 in the French Hospital Database on HIV. The Andersen and Gill model was used to calculate the adjusted hazard ratios (HRs), focusing on heavy alcohol use and neutrophil function-altering comorbidities. RESULTS Of 25 795 participants, 1414 developed 1883 severe bacterial infections. Between 2006 and 2009 and 2013 and 2015, the incidence fell from 13.2 (95% confidence interval [CI], 12.3-14.1) to 7.1 (95% CI, 6.3-7.8) per 1000 person-years. Heavy alcohol use was associated with an increased risk of severe bacterial infection (HR = 1.3, 95% CI = 1.1-1.7 for 40-80 g/day and HR = 1.6, 95% CI = 1.2-2.1 for >80 g/day), as were diabetes, chronic kidney disease, and end-stage liver disease (HR = 1.2, 95% CI = 1.0-1.4 when 1 comorbidity; HR = 2.3, 95% CI = 1.6-3.4 when more than 1 comorbidity), and nonacquired immune deficiency syndrome-defining malignancy (HR = 2.0; 95% CI, 1.6-2.4). CONCLUSIONS Heavy alcohol use was associated with an increased risk of severe bacterial infection, as were neutrophil function-altering comorbidities. Controlled-drinking approaches should be promoted and comorbidity management should be strengthened in PWH.
Collapse
Affiliation(s)
- Hugues Melliez
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.,Hôpital Gustave Dron, Service Universitaire des Maladies Infectieuses et du Voyageur, Tourcoing, France.,Hôpital de la Région de Saint-Omer, Service de Médecine Interne, Helfaut, France
| | - Murielle Mary-Krause
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - Marguerite Guiguet
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| | - Patrizia Carrieri
- Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques et Sociales de la Santé et Traitement de l'Information Médicale, Marseille, France.,ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte d'Azur, Marseille, France
| | - Sophie Abgrall
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Antoine Béclère, Service de Médecine Interne et Immunologie Clinique, Clamart, France
| | - Patricia Enel
- Hôpital de la Conception, Service d'Information Médicale, Marseille, France
| | - Sébastien Gallien
- AP-HP, Hôpital Henri Mondor, Service d'Immunologie Clinique et Maladies Infectieuses, Créteil, France
| | - Xavier Duval
- AP-HP, Hôpital Bichat-Claude Bernard, Service des Maladies Infectieuses et Tropicales, Paris, France
| | - Claudine Duvivier
- Institut Pasteur, Centre Médical de l'Institut Pasteur, Centre d'Infectiologie Necker-Pasteur, Paris, France
| | - Juliette Pavie
- AP-HP, Hôpital Européen Georges Pompidou, Service d'Immunologie Clinique, Paris, France
| | - Martin Siguier
- AP-HP, Service des Maladies Infectieuses, Hôpital Saint-Louis, Paris, France
| | | | - Pierre Tattevin
- Hôpital Pontchaillou, Service de des Maladies Infectieuses et Réanimation Médicale, Rennes, France
| | - Dominique Costagliola
- Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France
| |
Collapse
|
3
|
Boëlle PY, Delory T, Maynadier X, Janssen C, Piarroux R, Pichenot M, Lemaire X, Baclet N, Weyrich P, Melliez H, Meybeck A, Lanoix JP, Robineau O. Trajectories of Hospitalization in COVID-19 Patients: An Observational Study in France. J Clin Med 2020; 9:E3148. [PMID: 33003375 PMCID: PMC7600846 DOI: 10.3390/jcm9103148] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Revised: 09/20/2020] [Accepted: 09/27/2020] [Indexed: 12/16/2022] Open
Abstract
Describing the characteristics of COVID-19 patients in the hospital is of importance to assist in the management of hospital capacity in the future. Here, we analyze the trajectories of 1321 patients admitted to hospitals in northern and eastern France. We found that the time from onset to hospitalization decreased with age, from 7.3 days in the 20-65 year-olds to 4.5 in the >80 year-olds (p < 0.0001). Overall, the length of stay in the hospital was 15.9 days, and the death rate was 20%. One patient out of four was admitted to the intensive care unit (ICU) for approximately one month. The characteristics of trajectories changed with age: fewer older patients were admitted to the ICU and the death rate was larger in the elderly. Admission shortly after onset was associated with increased mortality (odds-ratio (OR) = 1.8, Confidence Interval (CI) 95% [1.3, 2.6]) as well as male sex (OR = 2.1, CI 95% [1.5, 2.9]). Time from admission within the hospital to the transfer to ICU was short. The age- and sex-adjusted mortality rate decreased over the course of the epidemic, suggesting improvement in care over time. In the SARS-CoV-2 epidemic, the urgent need for ICU at admission and the prolonged length of stay in ICU are a challenge for bed management and organization of care.
Collapse
Affiliation(s)
- Pierre-Yves Boëlle
- Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique, INSERM, Assistance Publique – Hôpitaux de Paris, 75012 Paris, France; (T.D.); (X.M.); (R.P.)
| | - Tristan Delory
- Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique, INSERM, Assistance Publique – Hôpitaux de Paris, 75012 Paris, France; (T.D.); (X.M.); (R.P.)
- Centre Hospitalier Annecy Genevois, 74370 Epagny–Metz-Tessy, France;
| | - Xavier Maynadier
- Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique, INSERM, Assistance Publique – Hôpitaux de Paris, 75012 Paris, France; (T.D.); (X.M.); (R.P.)
| | - Cécile Janssen
- Centre Hospitalier Annecy Genevois, 74370 Epagny–Metz-Tessy, France;
| | - Renaud Piarroux
- Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique, INSERM, Assistance Publique – Hôpitaux de Paris, 75012 Paris, France; (T.D.); (X.M.); (R.P.)
| | - Marie Pichenot
- Centre Hospitalier Victor Provot, 59100 Roubaix, France;
| | - Xavier Lemaire
- Service Maladies infectieuses, Centre Hospitalier de Douai, 59500 Douai, France;
| | - Nicolas Baclet
- Department of Infectious Diseases, Lille Catholic Hospitals, F-59160 Lille, France; (N.B.); (P.W.)
| | - Pierre Weyrich
- Department of Infectious Diseases, Lille Catholic Hospitals, F-59160 Lille, France; (N.B.); (P.W.)
| | - Hugues Melliez
- Service de médecine interne, Hôpital de la région de Saint-Omer, 62570 Helfaut, France;
| | - Agnès Meybeck
- Service Universitaire des maladies Infectieuses et du Voyageur, 59200 Tourcoing, France;
| | - Jean-Philippe Lanoix
- Service de Maladies Infectieuses et tropicales, CHU Amiens-Picardie, 80000 Amiens, France;
- AGIR UR UPJV 4294, CURS, Université Picardie Jules Verne, 80000 Amiens, France
| | - Olivier Robineau
- Sorbonne Université, Institut Pierre Louis d’Epidémiologie et de Santé Publique, INSERM, Assistance Publique – Hôpitaux de Paris, 75012 Paris, France; (T.D.); (X.M.); (R.P.)
- Service Universitaire des maladies Infectieuses et du Voyageur, 59200 Tourcoing, France;
| |
Collapse
|
4
|
Melliez H, Mary-Krause M, Guiguet M, Carrieri P, Abgrall S, Enel P, Gallien S, Duval X, Tattevin P, Costagliola D. Risque d’infection bactérienne sévère chez les PVVIH à l’ère des cART. Med Mal Infect 2020. [DOI: 10.1016/j.medmal.2020.06.303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
5
|
Melliez H, Prost M, Behal H, Neveux N, Benoist JF, Kim I, Mazzella S, Derdour V, Sauser E, Robineau O, Senneville E, Cynober L, Biekre R, Seguy D. Hypervitaminosis A is associated with immunological non-response in HIV-1-infected adults: a case-control study. Eur J Clin Microbiol Infect Dis 2020; 39:2091-2098. [PMID: 32607910 DOI: 10.1007/s10096-020-03954-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2020] [Accepted: 06/15/2020] [Indexed: 11/30/2022]
Abstract
For people living with HIV, determinants of immunological non-response (INR) to combined antiretroviral therapy (cART) have not been fully elucidated. In a case-control study, we evaluated the influence of the nutritional and antioxidant status in HIV-1 adults whose cART was initiated between January 2001 and December 2013. Cases had persistent CD4 counts < 350/μL vs. > 350/μL for controls, after at least 2 years of cART with persistent viral loads (VL) < 50 copies/mL. Twelve cases and twenty-eight control subjects with the same CD4 count at cART initiation were compared for their nutritional and antioxidant status after age adjustment at dosage assessment. Patients were predominantly male (70%), Caucasian (82%) and at AIDS stage (62%). The median age was 53, and the median CD4 count was 245/mm3 for cases and 630/mm3 for controls after a median time of 7 years on cART. Despite higher energy intakes in cases, anthropometric data was comparable between groups who had similar vitamins B9/B12/C/D/E, zinc, citrulline and glutamine levels. Nine cases (75%) and 8 controls (29%) had hypervitaminosis A (> 2.70 μmol/L) (p = 0.030). Cases had lower erythrocyte resistance when exposed to a controlled free radical attack (p = 0.014). Most cases had hypervitaminosis A and altered antioxidant capacities that could affect immunological response. Wide-scale studies are required, but in the meantime, screening of their vitamin A status must be encouraged in these patients.
Collapse
Affiliation(s)
- Hugues Melliez
- Hôpital Gustave Dron, Service universitaire des maladies infectieuses et du voyageur, Tourcoing, France. .,Hôpital de la région de Saint-Omer, Service de médecine interne, Helfaut, France.
| | | | - Hélène Behal
- CHU Lille, ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, University Lille, F-59000, Lille, France
| | - Nathalie Neveux
- Service de Biochimie, Hôpital Cochin, APHP et Service de Nutrition, Faculté de Pharmacie, Université de Paris, Paris, France
| | - Jean-François Benoist
- Biochimie hormonologie, Hôpital Universitaire Robert Debré APHP, Paris, France.,Lip (Sys)2, Université Paris-Sud, Chatenay Malabry, France
| | - Isabelle Kim
- Centre de Pathologies-Biologie, CHRU de Lille, Lille, France
| | - Sylvie Mazzella
- Hôpital Gustave Dron, Service universitaire des maladies infectieuses et du voyageur, Tourcoing, France
| | - Vincent Derdour
- Hôpital Gustave Dron, Service universitaire des maladies infectieuses et du voyageur, Tourcoing, France
| | - Evelyne Sauser
- Laboratoire d'Analyses Médicales, CH Dron, Tourcoing, France
| | - Olivier Robineau
- Hôpital Gustave Dron, Service universitaire des maladies infectieuses et du voyageur, Tourcoing, France
| | - Eric Senneville
- Hôpital Gustave Dron, Service universitaire des maladies infectieuses et du voyageur, Tourcoing, France
| | - Luc Cynober
- Service de Biochimie, Hôpital Cochin, APHP et Service de Nutrition, Faculté de Pharmacie, Université de Paris, Paris, France
| | - Raphaël Biekre
- Hôpital Gustave Dron, Service universitaire des maladies infectieuses et du voyageur, Tourcoing, France
| | - David Seguy
- U1286 - Infinite - Institute for Translational Research in Inflammation, University Lille, F-59000, Lille, France.,Inserm, U1286, F-59000, Lille, France.,CHU Lille, Endocrinologie, Diabétologie, Maladies Métabolique et Nutrition, F-59000, Lille, France
| |
Collapse
|
6
|
Melliez H, Mary-Krause M, Bocket L, Guiguet M, Abgrall S, De Truchis P, Katlama C, Martin-Blondel G, Henn A, Revest M, Robineau O, Khuong-Josses MA, Canestri A, De Castro N, Joly V, Mokhtari S, Risso K, Gasnault J, Costagliola D. Risk of Progressive Multifocal Leukoencephalopathy in the Combination Antiretroviral Therapy Era in the French Hospital Database on Human Immunodeficiency Virus (ANRS-C4). Clin Infect Dis 2019; 67:275-282. [PMID: 29635465 DOI: 10.1093/cid/ciy074] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2017] [Accepted: 01/29/2018] [Indexed: 12/31/2022] Open
Abstract
Background Risk factors for progressive multifocal leukoencephalopathy (PML) in individuals with human immunodeficiency virus (HIV) infection are poorly documented in the era of combination antiretroviral therapy (cART). Methods We studied HIV-1-infected individuals aged ≥15 years who had no history of PML and were prospectively followed up between 1997 and 2011 in the French Hospital Database on HIV (FHDH-ANRS CO4) cohort. Cox models were used to calculate adjusted hazard ratios (HRs), focusing on sub-Saharan origin, suggested to be protective, and recent cART initiation, potentially associated with an increased risk of PML. Results PML developed in 555 individuals, in 57 during the first 6 months of cART. From 1997-2000 to 2009-2011, the incidence fell from 1.15 (95% confidence interval [CI], .98-1.31) to 0.49 (.37-.61) per 1000 person-years. Sub-Saharan African origin had no clear influence (HR, 0.80; 95% CI, .58-1.11). Compared with men who have sex with men, injection drug users (IDUs) were at higher risk (HR, 1.80 [95% CI, 1.32-2.45] for male and 1.68 [1.13-2.48] for female IDUs). When IDUs were excluded, hepatitis C virus seropositivity was associated with an increased risk (HR, 1.40; 95% CI, 1.02-1.93). Compared with no cART initiation, initiation <6 months previously was associated with PML onset (HR, 4.91; 95% CI, 2.42-9.95). Conclusions Recent cART initiation is associated with an increased risk of PML, as are injection drug use and hepatitis C virus seropositivity. Sub-Saharan African origin had no protective effect.
Collapse
Affiliation(s)
- Hugues Melliez
- Sorbonne Universités, UPMC Université Paris, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique.,Service Universitaire des Maladies Infectieuses et du Voyageur, Hopital Gustave Dron, Tourcoing
| | - Murielle Mary-Krause
- Sorbonne Universités, UPMC Université Paris, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique
| | - Laurence Bocket
- Centre de Pathologies-Biologie, Centre Hospitalier Regional et Universitaire, Lille
| | - Marguerite Guiguet
- Sorbonne Universités, UPMC Université Paris, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique
| | - Sophie Abgrall
- Sorbonne Universités, UPMC Université Paris, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique.,Service de Médecine Interne et Immunologie Clinique, Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris (AP-HP), Clamart
| | | | - Christine Katlama
- Sorbonne Universités, UPMC Université Paris, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique.,Département des Maladies Infectieuses et Tropicales, Hôpital Pitié Salpêtrière, AP-HP, Paris
| | - Guillaume Martin-Blondel
- Service des Maladies Infectieuses et Tropicales, CHU de Toulouse.,Centre de Physiopathologie de Toulouse Purpan, INSERM UMR
| | - Aurelia Henn
- Service d'Immunologie Clinique et Maladies Infectieuses, Hôpital Henri Mondor, AP-HP, Créteil
| | - Matthieu Revest
- Service de Maladies Infectieuses et Réanimation Médicale, Hôpital Pontchaillou, Rennes
| | - Olivier Robineau
- Service Universitaire des Maladies Infectieuses et du Voyageur, Hopital Gustave Dron, Tourcoing
| | | | - Anna Canestri
- Service des Maladies infectieuses et tropicales, Hôpital Tenon
| | | | - Véronique Joly
- Hôpital Bichat, Service des Maladies Infectieuses et Tropicales, AP-HP, Paris
| | - Saadia Mokhtari
- Service des Maladies Infectieuses et Tropicales, Hôpital Nord, Marseille
| | - Karine Risso
- Service d'Infectiologie, Hôpital de l'Archet, Nice
| | - Jacques Gasnault
- Service de Médecine Interne, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicêtre, France
| | - Dominique Costagliola
- Sorbonne Universités, UPMC Université Paris, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique
| | | |
Collapse
|
7
|
Jeulin H, Jeanmaire E, Murray JM, Malve B, André M, Melliez H, Lanoix JP, Hustache-Mathieu L, Partisani M, Goehringer F, May T, Schvoerer E. Treatment as prevention enrolling at least 75% of individuals on ART will be needed to significantly reduce HIV prevalence in a HIV cohort. J Clin Virol 2019; 120:27-32. [PMID: 31541773 DOI: 10.1016/j.jcv.2019.08.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Revised: 07/01/2019] [Accepted: 08/23/2019] [Indexed: 10/26/2022]
Abstract
BACKGROUND "Treatment as Prevention" (TasP) aims to reduce new HIV infections through higher enrolment on suppressive antiretroviral therapy (ART). OBJECTIVES We studied the current epidemic and possible impact of TasP in a French HIV cohort including MSM and migrant subjects. STUDY DESIGN Socio-demographic, clinical and laboratory variables were collected during the follow-up of 6995 HIV-infected patients. The numbers of individuals living with HIV in each year were estimated from diagnoses up to that year minus recorded deaths. Patients were classified according to gender, transmission mode, country of birth and treatment status. RESULTS The cohort includes 6995 individuals diagnosed from 1985 to 2015, of whom 72% were men. Unprotected sexual intercourse was the main mode of transmission. Women were more likely to be migrants (45% versus 13%), whereas men were more likely to have been born in France (52% versus 27%). Diagnoses were more correlated with untreated than treated prevalence in each group. MSM diagnoses was strongly correlated to untreated prevalence whatever the country of birth (p < 0.0001). However, heterosexual diagnoses were better correlated with prevalence within individual country groups (b = 0.29 female diagnoses/year per untreated male born in France, compared to b = 0.73 for foreigners). Using these transmission rates, mathematical modelling estimated that enrolling 75% of untreated individuals per year would decrease diagnoses ten-fold by 2021. CONCLUSIONS Enrolling at least 75% of individuals on ART is necessary to substantially impact numbers of new HIV infections in this cohort. Treatment as prevention will actually be effective to reduce HIV prevalence.
Collapse
Affiliation(s)
- Hélène Jeulin
- Laboratoire de Virologie, Hôpital Brabois, CHRU de Nancy, Vandoeuvre-les-Nancy, France; LCPME (Laboratoire de Chimie Physique et Microbiologie pour les Matériaux et l'Environnement), UMR 7564, Faculté de Pharmacie, Nancy, F-54000, France
| | - Eliette Jeanmaire
- Service de Maladies Infectieuses et Tropicales, Hôpital Brabois, CHRU de Nancy, Vandoeuvre-les-Nancy, France
| | - John M Murray
- School of Mathematics and Statistics, UNSW Sydney, NSW, 2052, Australia; Cancer Research Division, Cancer Council NSW, Woolloomooloo, NSW, 2021, Australia
| | - Brice Malve
- Laboratoire de Virologie, Hôpital Brabois, CHRU de Nancy, Vandoeuvre-les-Nancy, France
| | - Marie André
- Service de Maladies Infectieuses et Tropicales, Hôpital Brabois, CHRU de Nancy, Vandoeuvre-les-Nancy, France
| | - Hugues Melliez
- Service de Maladies Infectieuses et Tropicales, Hôpital Guy Chatiliez, CH Tourcoing, Tourcoing, France
| | | | | | - Marialuisa Partisani
- HIV Infection care Center, Hôpitaux Universitaires Strasbourg, Strasbourg, France
| | - François Goehringer
- Service de Maladies Infectieuses et Tropicales, Hôpital Brabois, CHRU de Nancy, Vandoeuvre-les-Nancy, France
| | - Thierry May
- Service de Maladies Infectieuses et Tropicales, Hôpital Brabois, CHRU de Nancy, Vandoeuvre-les-Nancy, France
| | - Evelyne Schvoerer
- Laboratoire de Virologie, Hôpital Brabois, CHRU de Nancy, Vandoeuvre-les-Nancy, France; LCPME (Laboratoire de Chimie Physique et Microbiologie pour les Matériaux et l'Environnement), UMR 7564, Faculté de Pharmacie, Nancy, F-54000, France.
| |
Collapse
|
8
|
Robineau O, Alidjinou K, Meybeck A, Huleux T, Melliez H, Choisy P, Bocket L, Ajana F. Facteurs associés à la baisse de l’ADN proviral du VIH-1 chez les patients virologiquement contrôlés. Med Mal Infect 2018. [DOI: 10.1016/j.medmal.2018.04.382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Lopez B, Boucher A, Bahuaud M, Mortuaire G, Melliez H, Launay D, Terriou L, Wemeau-Stervinou L, Wallaert B, Faure K, Wallet F, Hachulla E, Hatron PY, Dubucquoi S, Batteux F, Labalette M, Lefèvre G. Specific Polysaccharide Antibody Deficiency Revealed by Severe Bacterial Infections in Adulthood: A Report on 11 Cases. Clin Infect Dis 2018; 65:328-331. [PMID: 28379361 DOI: 10.1093/cid/cix284] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2016] [Accepted: 03/28/2017] [Indexed: 11/15/2022] Open
Abstract
We report on 11 cases of specific polysaccharide antibody deficiency (SPAD) revealed in adulthood by severe infections with encapsulated bacteria. Given that immunoglobulin replacement therapy can effectively prevent the recurrence of bacterial infections in this context, SPAD should be considered once other antibody deficiencies have been ruled out.
Collapse
Affiliation(s)
- Benjamin Lopez
- CHU Lille, Institut d'Immunologie
- University of Lille, Inflammation Research International Center
| | - Anne Boucher
- CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares
| | - Mathilde Bahuaud
- CHU Hôpital Cochin, Laboratoire d'Immunologie biologique, Plateforme d'Immuno-monitoring Vaccinal, Paris
| | | | - Hugues Melliez
- Service Universitaire Régional de Maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, Tourcoing
| | - David Launay
- University of Lille, Inflammation Research International Center
- CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares
| | - Louis Terriou
- University of Lille, Inflammation Research International Center
| | - Lidwine Wemeau-Stervinou
- CHU Lille, Service de Pneumologie et Immuno-Allergologie, Centre de compétence Maladies Pulmonaires Rares
| | - Benoît Wallaert
- CHU Lille, Service de Pneumologie et Immuno-Allergologie, Centre de compétence Maladies Pulmonaires Rares
| | | | | | - Eric Hachulla
- University of Lille, Inflammation Research International Center
- CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares
| | - Pierre-Yves Hatron
- CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares
| | - Sylvain Dubucquoi
- CHU Lille, Institut d'Immunologie
- University of Lille, Inflammation Research International Center
| | - Frédéric Batteux
- CHU Hôpital Cochin, Laboratoire d'Immunologie biologique, Plateforme d'Immuno-monitoring Vaccinal, Paris
| | - Myriam Labalette
- CHU Lille, Institut d'Immunologie
- University of Lille, Inflammation Research International Center
| | - Guillaume Lefèvre
- CHU Lille, Institut d'Immunologie
- University of Lille, Inflammation Research International Center
- CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares
| |
Collapse
|
10
|
Lopez B, Boucher A, Bahuaud M, Mortuaire G, Melliez H, Launay D, Terriou L, Wemeau-Stervinou L, Wallaert B, Faure K, Wallet F, Hachulla E, Hatron PY, Dubucquoi S, Batteux F, Labalette M, Lefèvre G. Reply to Gilchrist et al. and to Musher. Clin Infect Dis 2018; 66:637-638. [PMID: 29401278 DOI: 10.1093/cid/cix866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Benjamin Lopez
- CHU Lille, Institut d'Immunologie.,Univ. Lille, U995 - LIRIC - Lille Inflammation Research International Center
| | - Anne Boucher
- CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares
| | - Mathilde Bahuaud
- CHU Hôpital Cochin, Laboratoire d'Immunologie biologique, Plateforme d'Immuno-monitoring Vaccinal, AP-HP, Paris
| | | | - Hugues Melliez
- Service Universitaire Régional de Maladies Infectieuses et du Voyageur, Centre Hospitalier Gustave Dron, Tourcoing
| | - David Launay
- Univ. Lille, U995 - LIRIC - Lille Inflammation Research International Center.,CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares
| | - Louis Terriou
- Univ. Lille, U995 - LIRIC - Lille Inflammation Research International Center
| | - Lidwine Wemeau-Stervinou
- CHU Lille, Service de Pneumologie et Immuno-Allergologie, Centre de compétence Maladies Pulmonaires Rares
| | - Benoît Wallaert
- CHU Lille, Service de Pneumologie et Immuno-Allergologie, Centre de compétence Maladies Pulmonaires Rares
| | | | | | - Eric Hachulla
- Univ. Lille, U995 - LIRIC - Lille Inflammation Research International Center.,CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares
| | - Pierre-Yves Hatron
- CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares
| | - Sylvain Dubucquoi
- CHU Lille, Institut d'Immunologie.,Univ. Lille, U995 - LIRIC - Lille Inflammation Research International Center
| | - Frédéric Batteux
- CHU Hôpital Cochin, Laboratoire d'Immunologie biologique, Plateforme d'Immuno-monitoring Vaccinal, AP-HP, Paris
| | - Myriam Labalette
- CHU Lille, Institut d'Immunologie.,Univ. Lille, U995 - LIRIC - Lille Inflammation Research International Center
| | - Guillaume Lefèvre
- CHU Lille, Institut d'Immunologie.,Univ. Lille, U995 - LIRIC - Lille Inflammation Research International Center.,CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre National de Référence Maladies Systémiques et Auto-immunes Rares
| |
Collapse
|
11
|
Pradat P, Pugliese P, Poizot-Martin I, Valantin MA, Cuzin L, Reynes J, Billaud E, Huleux T, Bani-Sadr F, Rey D, Frésard A, Jacomet C, Duvivier C, Cheret A, Hustache-Mathieu L, Hoen B, Cabié A, Cotte L, Chidiac C, Ferry T, Ader F, Biron F, Boibieux A, Miailhes P, Perpoint T, Schlienger I, Lippmann J, Braun E, Koffi J, Longuet C, Guéripel V, Augustin-Normand C, Brochier C, Degroodt S, Pugliese P, Ceppi C, Cua E, Cottalorda J, Courjon J, Dellamonica P, Demonchy E, De Monte A, Durant J, Etienne C, Ferrando S, Fuzibet J, Garraffo R, Joulie A, Risso K, Mondain V, Naqvi A, Oran N, Perbost I, Pillet S, Prouvost-Keller B, Wehrlen-Pugliese S, Rosenthal E, Sausse S, Rio V, Roger P, Brégigeon S, Faucher O, Obry-Roguet V, Orticoni M, Soavi M, Geneau de Lamarlière P, Laroche H, Ressiot E, Carta M, Ducassou M, Jacquet I, Gallie S, Galinier A, Ritleng A, Ivanova A, Blanco-Betancourt C, Lions C, Debreux C, Obry-Roguet V, Poizot-Martin I, Agher R, Katlama C, Valantin M, Duvivier C, Lortholary O, Lanternier F, Charlier C, Rouzaud C, Aguilar C, Henry B, Lebeaux D, Cessot G, Gergely A, Consigny P, Touam F, Louisin C, Alvarez M, Biezunski N, Cuzin L, Debard A, Delobel P, Delpierre C, Fourcade C, Marchou B, Martin-Blondel G, Porte M, Mularczyk M, Garipuy D, Saune K, Lepain I, Marcel M, Puntis E, Atoui N, Casanova M, Faucherre V, Jacquet J, Le Moing V, Makinson A, Merle De Boever C, Montoya-Ferrer A, Psomas C, Reynes J, Raffi F, Allavena C, Billaud E, Biron C, Bonnet B, Bouchez S, Boutoille D, Brunet C, Jovelin T, Hall N, Bernaud C, Morineau P, Reliquet V, Aubry O, Point P, Besnier M, Larmet L, Hüe H, Pineau S, André-Garnier E, Rodallec A, Choisy P, Vandame S, Huleux T, Ajana F, Alcaraz I, Baclet V, Huleux T, Melliez H, Viget N, Valette M, Aissi E, Allienne C, Meybeck A, Riff B, Bani-Sadr F, Rouger C, Berger J, N'Guyen Y, Lambert D, Kmiec I, Hentzien M, Lebrun D, Migault C, Rey D, Batard M, Bernard-Henry C, Cheneau C, de Mautort E, Fischer P, Partisani M, Priester M, Lucht F, Frésard A, Botelho-Nevers E, Gagneux-Brunon A, Cazorla C, Guglielminotti C, Daoud F, Lutz M, Jacomet C, Laurichesse H, Lesens O, Vidal M, Mrozek N, Corbin V, Aumeran C, Baud O, Casanova S, Coban D, Hustache-Mathieu L, Thiebaut-Drobacheff M, Foltzer A, Gendrin V, Bozon F, Chirouze C, Abel S, Cabié A, Césaire R, Santos GD, Fagour L, Najioullah F, Ouka M, Pierre-François S, Pircher M, Rozé B, Hoen B, Ouissa R, Lamaury I. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"? J Infect 2017; 75:234-241. [PMID: 28579302 DOI: 10.1016/j.jinf.2017.05.008] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2016] [Revised: 03/17/2017] [Accepted: 05/11/2017] [Indexed: 02/07/2023]
Abstract
OBJECTIVES Direct-Acting Antivirals (DAAs) opened a new era in HCV treatment. We report the impact of HCV treatment in French HIV-HCV coinfected patients. METHODS All HIV-HCV patients from the Dat'AIDS cohort followed between 2012 and 2015 were included. HCV status was defined yearly as naive, spontaneous cure, sustained virological response (SVR12), failure or reinfection. RESULTS Among 32,945 HIV-infected patients, 15.2% were positive for anti-HCV antibodies. From 2012 to 2015, HCV incidence rate increased from 0.35%PY to 0.69%PY in MSM, while median incidence was 0.08%PY in other patients. Median reinfection rate was 2.56%PY in MSM and 0.22%PY in other patients. HCV treatment initiation rate rose from 8.2% in 2012 to 29.6% (48.0% in pre-treated patients vs 22.6% in naïve patients). SVR12 rate increased from 68.7% to 95.2%. By the end of 2015, 62.7% of the patients were cured either spontaneously or following SVR. CONCLUSIONS HCV treatment dramatically increased in HIV-HCV patients in France from 2012 to 2015 resulting in HCV cure in nearly two-thirds of the patients in this cohort. Combined with a declining HCV prevalence, the prevalence of active HCV infection among HIV patients will drastically decrease in the forthcoming years.
Collapse
Affiliation(s)
- Pierre Pradat
- Center for Clinical Research, Department of Hepatology, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France.
| | - Pascal Pugliese
- Department of Infectious Diseases, Centre Hospitalier Universitaire de Nice, Hôpital l'Archet, Nice, France
| | - Isabelle Poizot-Martin
- Immuno-hematology Clinic, Assistance Publique - Hôpitaux de Marseille, Hôpital Sainte-Marguerite, Marseille, France; Aix-Marseille University, Inserm U912 (SESSTIM), Marseille, France
| | - Marc-Antoine Valantin
- Department of Infectious Diseases, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France; Sorbonne Universités, UPMC Université Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France
| | - Lise Cuzin
- CHU Toulouse, COREVIH, Toulouse, France; Université de Toulouse III, Toulouse, France; INSERM, UMR, 1027, Toulouse, France
| | - Jacques Reynes
- Department of Infectious Diseases, UMI 233 INSERM U1175, CHU de Montpellier, Montpellier, France
| | - Eric Billaud
- Department of Infectious Diseases, Hotel Dieu Hospital, Nantes, France
| | - Thomas Huleux
- Department of Infectious Diseases and Travel Diseases, Centre Hospitalier Gustave-Dron, Tourcoing, France
| | - Firouze Bani-Sadr
- Department of Internal Medicine, Infectious Diseases and Clinical Immunology, Hôpital Robert Debré, CHU, Reims, France; Université de Reims Champagne-Ardenne, Faculté de médecine, EA-4684/SFR CAP-SANTE, Reims, France
| | - David Rey
- HIV Infection Care Centre, Hôpitaux Universitaires, Strasbourg, France
| | - Anne Frésard
- Department of Infectious Diseases, CHU, Saint-Etienne, France
| | - Christine Jacomet
- Department of Infectious Diseases, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Claudine Duvivier
- Department of Infectious Diseases, Centre d'Infectiologie Necker-Pasteur, IHU Imagine, Assistance Publique - Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, EA7327, Paris, France
| | - Antoine Cheret
- Department of Internal Medicine, CHU, Bicètre, France; Université Paris Descartes, Sorbonne Paris Cité, EA7327, Paris, France
| | | | - Bruno Hoen
- Faculté de Médecine Hyacinthe Bastaraud, Université des Antilles, and Service de Maladies Infectieuses et Tropicales, Dermatologie et Médecine Interne, and Inserm CIC 1424, Centre Hospitalier Universitaire de Pointe-à-Pitre, Pointe-à-Pitre, France
| | - André Cabié
- Department of Infectious Diseases, CHU de Martinique, Fort-de-France, France; Université des Antilles EA4537 and INSERM CIC1424, Fort-de-France, France
| | - Laurent Cotte
- Department of Infectious Diseases, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France; INSERM U1052, Lyon, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Lopez B, Boucher A, Bahuaud M, Mortuaire G, Melliez H, Launay D, Terriou L, Stervinou-Wemeau L, Batteux F, Dubucquoi S, Labalette M, Lefèvre G. Déficit isolé en anticorps spécifiques antipolysaccharides, un déficit immunitaire humoral à ne pas méconnaître en cas d’infections graves à germes encapsulés : à propos de cinq observations. Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.04.247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Baclet V, Valette M, Meybeck A, Ajana F, Huleux T, Viget N, Alcaraz I, Melliez H, Senneville E. IST-12 - Estimation de la prévalence multisites de Chlamydia trachomatis et Neisseria gonorrheae et des facteurs associés chez les patients récemment découverts infectés par le VIH. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30443-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
14
|
Deconinck L, Meybeck A, Pradier M, Patoz P, Melliez H, Senneville E. Community acquired fungemia caused by Candida pulcherrima: diagnostic contribution of MALDI-TOF mass spectrometry. Ann Clin Microbiol Antimicrob 2016; 15:14. [PMID: 26951431 PMCID: PMC4782459 DOI: 10.1186/s12941-016-0129-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Accepted: 02/29/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Community-onset candidemia constitute a distinct clinical entity the incidence of which is increasing. Contribution of non-albicans Candida species is rising. CASE PRESENTATION We describe here the first reported case of community acquired fungemia due to Candida pulcherrima. Identification to the species level was performed by MALDI-TOF mass spectrometry. Treatment with fluconazole was successful. CONCLUSION This case confirms the pathogenic role of C. pulcherrima and the contribution of MALDI-TOF mass spectrometry for identification of rare Candida species.
Collapse
Affiliation(s)
- Laurène Deconinck
- Centre Hospitalier Dron, Service Universitaire des Maladies Infectieuses et du voyageur, 135 avenue du Président Coty, 59200, Tourcoing, France.
| | - Agnès Meybeck
- Centre Hospitalier Dron, Service Universitaire des Maladies Infectieuses et du voyageur, 135 avenue du Président Coty, 59200, Tourcoing, France.
| | - Maxime Pradier
- Centre Hospitalier Dron, Service Universitaire des Maladies Infectieuses et du voyageur, 135 avenue du Président Coty, 59200, Tourcoing, France.
| | - Pierre Patoz
- Laboratoire de biologie, Centre Hospitalier Dron, 135 avenue du Président Coty, 59200, Tourcoing, France.
| | - Hugues Melliez
- Centre Hospitalier Dron, Service Universitaire des Maladies Infectieuses et du voyageur, 135 avenue du Président Coty, 59200, Tourcoing, France.
| | - Eric Senneville
- Centre Hospitalier Dron, Service Universitaire des Maladies Infectieuses et du voyageur, 135 avenue du Président Coty, 59200, Tourcoing, France.
| |
Collapse
|
15
|
de la Tribonnière X, Broly F, Deuffic-Burban S, Bocket L, Ajana F, Viget N, Melliez H, Mouton Y, Yazdanpanah Y. ABCB1Allele Polymorphism Is Associated with Virological Efficacy in Naïve HIV-Infected Patients on HAART Containing Nonboosted PIs But Not Boosted PIs. HIV Clinical Trials 2015; 9:192-201. [DOI: 10.1310/hct0903-192] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
16
|
Deconinck L, Yazdanpanah Y, Gilson RJ, Melliez H, Viget N, Joly V, Sabin CA. Time to initiation of antiretroviral therapy in HIV-infected patients diagnosed with an opportunistic disease: a cohort study. HIV Med 2014; 16:219-29. [PMID: 25522796 DOI: 10.1111/hiv.12201] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/13/2014] [Indexed: 11/26/2022]
Abstract
OBJECTIVES The aim of the study was to identify factors associated with the time between opportunistic disease (OD) diagnosis and antiretroviral therapy (ART) initiation in HIV-infected patients presenting for care with an OD, and to evaluate the outcomes associated with any delay. METHODS A multicentre cohort study was undertaken in London, Paris and Lille/Tourcoing. The medical records of patients diagnosed from 2002 to 2012 were reviewed. RESULTS A total of 437 patients were enrolled in the study: 70% were male, the median age was 40 years, 42% were from sub-Saharan Africa, 68% were heterosexual, the median CD4 count was 40 cells/μL, and the most common ODs were Pneumocystis pneumonia (37%), tuberculosis (24%), toxoplasmosis (12%) and Kaposi's sarcoma (11%). Of these patients, 400 (92%) started ART within 24 weeks after HIV diagnosis, with a median time from OD diagnosis to ART initiation of 30 [interquartile range (IQR) 16-58] days. Patients diagnosed between 2009 and 2012 had a shorter time to ART initiation than those diagnosed in earlier years [hazard ratio (HR) 2.07; 95% confidence interval (CI) 1.58-2.72]. Factors associated with a longer time to ART initiation were a CD4 count ≥ 200 cells/μL (HR 0.30; 95% CI 0.20-0.44), tuberculosis (HR 0.40; 95% CI 0.30-0.55) and diagnosis in London (HR 0.62; 95% CI 0.48-0.80). Patients initiating 'deferred' ART (by ≥ 30 days) exhibited no difference in disease progression or immunovirological response compared with patients who had shorter times to ART initiation. Patients in the 'deferred' group were less likely to have ART modifications (HR 0.69; 95% CI 0.48-1.00) and had shorter in-patient stays (mean 14.2 days shorter; 95% CI 8.9-19.5 days) than patients in the group whose ART was not deferred. CONCLUSIONS The time between OD diagnosis and ART initiation remains heterogeneous and relatively long, particularly in individuals with a high CD4 count or tuberculosis or those diagnosed in London. Deferring ART was associated with fewer ART modifications and shorter in-patient stays.
Collapse
Affiliation(s)
- L Deconinck
- UCL Research Department of Infection and Population Health, University College London, London, UK; Decision Sciences in Infectious Disease: Prevention, Control, and Care, IAME, UMR 1137, Paris Diderot University, Sorbonne Paris Cité, Paris, France; Department of Infectious Diseases, Lille School of Medicine, Tourcoing Hospital, Tourcoing, France
| | | | | | | | | | | | | |
Collapse
|
17
|
Joseph C, Meybeck A, Melliez H, Boyer T, Fortin-Lebraud L, Lovi V, Douaud M, Pradier M, Senneville E. Tropical infection after a case of total hip arthroplasty. J Hosp Infect 2014; 87:179-81. [PMID: 24954916 DOI: 10.1016/j.jhin.2014.04.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2014] [Accepted: 04/29/2014] [Indexed: 11/17/2022]
Abstract
In non-endemic areas, malaria is mainly an imported disease. This article reports a case of transfusion-related Plasmodium falciparum malaria in a non-endemic area. Despite initial clinical signs consistent with malaria, the diagnosis was not elicited because of the absence of any identified epidemiological risk factors. The case indicates that transfusion-transmitted malaria still occurs in non-endemic countries. The role of laboratory testing to prevent and diagnose transfusion-transmitted malaria in non-endemic malaria countries is crucial.
Collapse
Affiliation(s)
- C Joseph
- Infectious Diseases Department, Dron Hospital, Tourcoing, France
| | - A Meybeck
- Infectious Diseases Department, Dron Hospital, Tourcoing, France.
| | - H Melliez
- Infectious Diseases Department, Dron Hospital, Tourcoing, France
| | - T Boyer
- Hematology and Transfusion Institute, University Hospital, Lille, France
| | | | - V Lovi
- Haemoviligance Department, Dron Hospital, Tourcoing, France
| | - M Douaud
- Infectious Diseases Department, Dron Hospital, Tourcoing, France
| | - M Pradier
- Infectious Diseases Department, Dron Hospital, Tourcoing, France
| | - E Senneville
- Infectious Diseases Department, Dron Hospital, Tourcoing, France
| |
Collapse
|
18
|
Alfandari S, Gois J, Delannoy PY, Georges H, Boussekey N, Chiche A, Meybeck A, Patoz P, Blondiaux N, Senneville E, Melliez H, Leroy O. Management and control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. Med Mal Infect 2014; 44:229-31. [PMID: 24840286 DOI: 10.1016/j.medmal.2014.03.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2014] [Revised: 03/23/2014] [Accepted: 03/24/2014] [Indexed: 10/25/2022]
Abstract
OBJECTIVE We had for aim to describe the identification and management of a 14-clonal carbapenem-resistant Acinetobacter baumannii (CRAB) outbreak, following admission of a known CRAB-infected patient in an ICU. METHODS We reviewed the carriers' files and outbreak management procedures. RESULTS The index patient was admitted with strict isolation precautions. The outbreak started 2 months after his discharge. It persisted despite reinforcement of strict isolation precautions, staff and patient cohorting, and extensive environmental decontamination including 2 rounds of routine terminal cleaning and disinfection or 1 round of cleaning and disinfection followed by hydrogen peroxide treatment. A second epidemic peak, after 4 weeks without any case, led to another wide environmental sampling and decontamination rounds. The source of the CRAB outbreak was suspected to be the blood pressure cuffs Velcro. Switching to cuffs submersible in a disinfectant stopped the outbreak. CONCLUSIONS CRAB outbreaks are difficult to manage and sources of persistent colonization can be unexpected.
Collapse
Affiliation(s)
- S Alfandari
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France.
| | - J Gois
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France
| | - P-Y Delannoy
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France
| | - H Georges
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France
| | - N Boussekey
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France
| | - A Chiche
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France
| | - A Meybeck
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France
| | - P Patoz
- Laboratoire de biologie, centre hospitalier de Tourcoing, 59208 Tourcoing, France
| | - N Blondiaux
- Laboratoire de biologie, centre hospitalier de Tourcoing, 59208 Tourcoing, France
| | - E Senneville
- Service universitaire des maladies infectieuses et du voyageur, centre hospitalier de Tourcoing, 59208 Tourcoing, France
| | - H Melliez
- Service universitaire des maladies infectieuses et du voyageur, centre hospitalier de Tourcoing, 59208 Tourcoing, France
| | - O Leroy
- Service de réanimation et des maladies infectieuses, centre hospitalier de Tourcoing, 155, rue du Président-Coty, 59208 Tourcoing cedex, France
| |
Collapse
|
19
|
Poissy J, Champenois K, Dewilde A, Melliez H, Georges H, Senneville E, Yazdanpanah Y. Impact of Herpes simplex virus load and red blood cells in cerebrospinal fluid upon herpes simplex meningo-encephalitis outcome. BMC Infect Dis 2012; 12:356. [PMID: 23245564 PMCID: PMC3560250 DOI: 10.1186/1471-2334-12-356] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2012] [Accepted: 12/14/2012] [Indexed: 11/23/2022] Open
Abstract
BACKGROUND Herpes simplex encephalitis (HSE) often leads to severe disability or death. Factors usually associated with outcome include Simplified Acute Physiology Score, age and delay of initiation of acyclovir treatment.Our aim was to determine the impact of Herpes simplex virus (HSV) load in cerebrospinal fluid (CSF) upon HSE outcome. METHODS We retrospectively determined HSV load in the CSF of 43 patients with confirmed HSE, hospitalized in northern France from 1998 to 2005, using CSF samples collected the day of hospital admission and stored at -20°C. We analyzed the association between HSV load and mortality/morbidity by the Glasgow Outcome Scale. Fisher's exact test and Wilcoxon's test were used for statistical analysis. RESULTS The M/F sex ratio was 1.7 and median patient age was 61 years. Median HSV load in CSF was 2.0 log copies/μL (IQR 25-75=1.2-2.6). The mortality rate was 32.6% six months after HSE diagnosis. Higher age was associated with mortality (p=0.03). Longer delay in acyclovir initiation tended to be associated with higher mortality but did not reach statistical significance (p=0.08). Severe disability and death due to HSV were associated with a higher Knaus score (p=0.004), later acyclovir initiation (p=0.006), older age (p=0.04) and presence of red blood cells in CSF (p=0.05). HSV load in CSF was neither associated with mortality (p=1.00) nor with morbidity (p=0.90). CONCLUSION In this study, HSV load in CSF was not found to be associated with poor outcome in patients with HSE. These data do not support measurement of HSV load at admission in patients with HSE.
Collapse
Affiliation(s)
- Julien Poissy
- Service universitaire de Maladies infectieuses et du Voyageur, Centre hospitalier de Tourcoing, France
| | - Karen Champenois
- Equipe ATIP/Avenir INSERM U995, Université Lille Nord de France, Lille, France
| | | | - Hugues Melliez
- Service universitaire de Maladies infectieuses et du Voyageur, Centre hospitalier de Tourcoing, France
| | - Hugues Georges
- Service de Réanimation polyvalente et des Maladies infectieuses, Centre hospitalier de Tourcoing, France
| | - Eric Senneville
- Service universitaire de Maladies infectieuses et du Voyageur, Centre hospitalier de Tourcoing, France
| | - Yazdan Yazdanpanah
- Service universitaire de Maladies infectieuses et du Voyageur, Centre hospitalier de Tourcoing, France
- Equipe ATIP/Avenir INSERM U995, Université Lille Nord de France, Lille, France
| |
Collapse
|
20
|
Charpentier C, Joly V, Larrouy L, Fagard C, Visseaux B, de Verdiere NC, Raffi F, Yeni P, Descamps D, Aumaitre H, Medus M, Neuville S, Saada M, Abgrall S, Bentata M, Bouchaud O, Cailhol J, Cordel H, Dhote R, Gros H, Honore-Berlureau P, Huynh T, Krivitzky A, Mansouri R, Poupard M, Prendki V, Radia D, Rouges F, Touam F, Warde B, de Castro N, Colin de Verdiere N, Delgado J, Ferret S, Gallien S, Kandel T, Lafaurie M, Lagrange M, Lascoux-Combe C, Le D, Molina JM, Pavie J, Pintado C, Ponscarme D, Rachline A, Rozenbaum W, Sereni D, Taulera O, Estavoyer JM, Faucher JF, Foltzer A, Hoen B, Hustache-Mathieu L, Dupon M, Dutronc H, Neau D, Ragnaud JM, Raymond I, Boucly S, Lortholary O, Viard JP, Bechara C, Delfraissy JF, Ghosn J, Goujard C, Kamouh W, Mole M, Quertainmont Y, Bergmann JF, Boulanger E, Castillo H, Parrinello M, Rami A, Sellier P, Lepeu G, Pichancourt G, Bernard L, Berthe H, Clarissou J, Gory M, Melchior JC, Perronne C, Stegman S, de Truchis P, Derradji O, Malet M, Teicher E, Vittecoq D, Chakvetadze C, Fontaine C, Lukiana T, Pialloux G, Slama L, Bonnet D, Boucherit S, El Alami Talbi N, Fournier I, Gervais A, Joly V, Iordache L, Laurichesse JJ, Leport C, Pahlavan G, Phung BC, Yeni P, Bennamar N, Brunet A, Guillevin L, Salmon-Ceron D, Tahi T, Chesnel C, Dominguez S, Jouve P, Lelievre JD, Levy Y, Melica G, Sobel A, Ben Abdallah S, Bonmarchand M, Bricaire F, Herson S, Iguertsira M, Katlama C, Kouadio H, Schneider L, Simon A, Valantin MA, Abel S, Beaujolais V, Cabie A, Liauthaud B, Pierre Francois S, Abgueguen P, Chennebault JM, Loison J, Pichard E, Rabier V, Delaune J, Louis I, Morlat P, Pertusa MC, Brunel-Delmas F, Chiarello P, Jeanblanc F, Jourdain JJ, Livrozet JM, Makhloufi D, Touraine JL, Augustin-Normand C, Bailly F, Benmakhlouf N, Brochier C, Cotte L, Gueripel V, Koffi K, Lack P, Lebouche B, Maynard M, Miailhes P, Radenne S, Schlienger I, Thoirain V, Trepo C, Drogoul MP, Fabre G, Faucher O, Frixon-Marin V, Gastaut JA, Peyrouse E, Poizot-Martin I, Jacquet JM, Le Facher G, Merle de Boever C, Reynes J, Tramoni C, Allavena C, Billaud E, Biron C, Bonnet B, Bouchez S, Boutoille D, Brunet-Francois C, Hue H, Mounoury O, Raffi F, Reliquet V, Aubry O, Esnault JL, Leautez-Nainville S, Perre P, Suaud I, Breaud S, Ceppi C, Dellamonica P, De Salvador F, Durant J, Ferrando S, Fuzibet JG, Leplatois A, Mondain V, Perbost I, Pugliese P, Rahelinirina V, Rosenthal E, Sanderson F, Vassalo M, Arvieux C, Chapplain JM, Michelet C, Ratajczak M, Revest M, Souala F, Tattevin P, Cheneau C, Fischer P, Lang JM, Partisani M, Rey D, Bastides F, Besnier JM, Le Bret P, Choutet P, Dailloux JF, Guadagnin P, Nau P, Rivalain J, Soufflet A, Aissi E, Melliez H, Pavel S, Mouton Y, Yazdanpanah Y, Boyer L, Burty C, Letranchant L, May T, Wassoumbou S, Blum L, Danne O, Arthus MA, Dion P, Certain A, Tabuteau S, Beuscart A, Agher N, Frosch A, Couffin-Cadiergues S, Diallo A. Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial. J Antimicrob Chemother 2012; 68:690-6. [DOI: 10.1093/jac/dks455] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Allavena C, Flandre P, Pugliese P, Valantin MA, Poizot-Martin I, Cabié A, Melliez H, Cuzin L, Duvivier C, Dellamonica P, Raffi F. Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort. ACTA ACUST UNITED AC 2011; 44:37-43. [DOI: 10.3109/00365548.2011.598870] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
22
|
Massongo M, Pasquet A, Huleux T, Aïssi E, Ettahar N, Yazdanpanah Y, Melliez H. [Immune reconstitution syndrome related to a Mycobacterium avium complex infection, revealed by a mono-adenitis]. Med Mal Infect 2011; 41:489-92. [PMID: 21840146 DOI: 10.1016/j.medmal.2011.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2010] [Revised: 05/08/2011] [Accepted: 07/06/2011] [Indexed: 11/29/2022]
Affiliation(s)
- M Massongo
- Service régional universitaire des maladies infectieuses et du voyageur, centre hospitalier Gustave-Dron, 135 rue du Président-Coty, Tourcoing, France.
| | | | | | | | | | | | | |
Collapse
|
23
|
Mallet M, Loiez C, Melliez H, Yazdanpanah Y, Senneville E, Lemaire X. Staphylococcus simulans as an authentic pathogenic agent of osteoarticular infections. Infection 2011; 39:473-6. [PMID: 21830134 DOI: 10.1007/s15010-011-0173-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2011] [Accepted: 07/27/2011] [Indexed: 01/18/2023]
Abstract
OBJECTIVES To evaluate the role of Staphylococcus simulans in bone and joint infections (BJI) and determine their main characteristics. METHODS A search of the database of the microbiology laboratories of Lille hospital and Tourcoing hospital was performed. Only results from blood, bone, and orthopedic device cultures were taken into account for hospitalized patients between January 2004 and January 2009. We considered cases in which S. simulans was the only bacteria isolated in all of the patients' biological samples with clinical and laboratory signs of infection. For patients with complete medical records, we recorded the clinical and epidemiological data. RESULTS Six cases of BJI due to S. simulans were recorded, with five cases related to orthopedic devices infections. Three patients lived in rural areas. In four out of six patients, S. simulans was isolated in intraoperative biopsy material. In one patient, S. simulans grew in synovial fluid and in another in blood cultures only. The latter patient had a spondylodiscitis, and chronic foot ulcers due to gout disease were suspected to be the origin of the infection. All patients were healed after a mean follow up of 9 ± 3 months. Orthopedic devices were removed in four of the five patients concerned. The combination of rifampicin plus levofloxacin was used in four patients. CONCLUSION The present data suggest that, even though S. simulans remains rarely observed in clinical pathology, its role in osteoarticular infections, especially in the case of infected orthopedic devices, is not exceptional. As for the antibiotic treatment, the combination of rifampicin and levofloxacin seems to be an effective strategy according to our clinical results.
Collapse
Affiliation(s)
- M Mallet
- Infectious Diseases Department, Dron Hospital, Tourcoing, France
| | | | | | | | | | | |
Collapse
|
24
|
Blanc AL, Vialle B, Lemaire X, Poissy J, Melliez H, François P, Senneville E, Yazdanpanah Y. [Chronic pyelonephritis and xanthogranulomatous pyelonephritis]. Med Mal Infect 2011; 41:339-42. [PMID: 21458176 DOI: 10.1016/j.medmal.2011.02.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2010] [Revised: 11/04/2010] [Accepted: 02/14/2011] [Indexed: 11/24/2022]
Affiliation(s)
- A-L Blanc
- Service universitaire de maladies infectieuses et du voyageur, centre hospitalier Tourcoing, 135, rue du Président-Coty, 59200 Tourcoing, France
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Ndiaye B, Salleron J, Vincent A, Bataille P, Bonnevie F, Choisy P, Cochonat K, Fontier C, Guerroumi H, Vandercam B, Melliez H, Yazdanpanah Y. Factors associated with presentation to care with advanced HIV disease in Brussels and Northern France: 1997-2007. BMC Infect Dis 2011; 11:11. [PMID: 21226905 PMCID: PMC3032693 DOI: 10.1186/1471-2334-11-11] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2010] [Accepted: 01/12/2011] [Indexed: 11/12/2022] Open
Abstract
Background Our objective was to determine the frequency and determinants of presentation to care with advanced HIV disease in patients who discover their HIV diagnosis at this stage as well as those with delayed presentation to care after HIV diagnosis in earlier stages. Methods We collected data on 1,819 HIV-infected patients in Brussels (Belgium) and Northern France from January 1997 to December 2007. "Advanced HIV disease" was defined as CD4 count <200/mm3 or clinically-defined AIDS at study inclusion and was stratified into two groups: (a) late testing, defined as presentation to care with advanced HIV disease and HIV diagnosis ≤6 months before initiation of HIV care; and (b) delayed presentation to care, defined as presentation to care with advanced HIV disease and HIV diagnosis >6 months before initiation of HIV care. We used multinomial logistic regression to determine the factors associated with delayed presentation to care and late testing. Results Of the 570 patients initiating care with advanced HIV disease, 475 (83.3%) were tested late and 95 (16.7%) had delayed presentation to care. Risk factors for delayed presentation to care were: age 30-50 years, injection drug use, and follow-up in Brussels. Risk factors for late testing were: sub-Saharan African origin, male gender, and older age. HIV transmission through heterosexual contact was associated with an increased risk of both delayed presentation to care and late testing. Patients who initiated HIV care in 2003-2007 were less likely to have been tested late or to have a delayed presentation to care than patients who initiated care before 2003. Conclusion A considerable proportion of HIV-infected patients present to care with advanced HIV disease. Late testing, rather than a delay in initiating care after earlier HIV testing, is the main determinant of presentation to care with advanced HIV disease. The factors associated with delay presentation to care differ from those associated with late testing. Different strategies should be developed to optimize early access to care in these two groups.
Collapse
|
26
|
Jit M, Mangen MJJ, Melliez H, Yazdanpanah Y, Bilcke J, Salo H, Edmunds WJ, Beutels P. An update to “The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe”. Vaccine 2010; 28:7457-9. [PMID: 20846529 DOI: 10.1016/j.vaccine.2010.08.060] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2010] [Revised: 08/06/2010] [Accepted: 08/11/2010] [Indexed: 11/20/2022]
|
27
|
Deuffic-Burban S, Atsou K, Viget N, Melliez H, Bouvet E, Yazdanpanah Y. Cost-effectiveness of QuantiFERON-TB test vs. tuberculin skin test in the diagnosis of latent tuberculosis infection. Int J Tuberc Lung Dis 2010; 14:471-481. [PMID: 20202306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023] Open
Abstract
OBJECTIVE To evaluate the cost-effectiveness of the tuberculin skin test (TST), the QuantiFERON-TB Gold test (QFT) and a combination of TST and QFT (TST+QFT) for diagnosing latent tuberculosis infection (LTBI) in France in a bacille Calmette-Guérin (BCG) vaccinated population. METHODS A decision analysis model evaluated three strategies among simulated adults in close contact with tuberculosis (TB). We calculated direct lifetime medical costs, life expectancies and incremental cost-effectiveness ratios (ICERs). RESULTS The discounted direct medical costs of care per patient of no testing, TST, QFT and TST+QFT were respectively euro417, euro476, euro443 and euro435, while discounted life expectancies were respectively 25.030, 25.071, 25.073 and 25.062 years. TST had higher costs and lower efficacy than QFT; TST+QFT was associated with an ICER of euro560 per year of life gained (YLG) compared to no testing, and QFT was associated with an ICER of euro730/YLG compared to TST+QFT. The only scenario where QFT was associated with an ICER of >euro75 000/YLG was when the prevalence of LTBI around TB was low (<5%) and TST specificity high (>90%). CONCLUSIONS In France, for the diagnosis of LTBI after close contact with TB, the TST is more expensive and less effective than QFT. Although it is more expensive, QFT is more effective and cost-effective than TST+QFT under a wide range of realistic test performance scenarios.
Collapse
Affiliation(s)
- S Deuffic-Burban
- Institut National de la Santé et de la Recherche Médicale (INSERM) U795, Faculté de Médecine, Lille, France.
| | | | | | | | | | | |
Collapse
|
28
|
Jit M, Bilcke J, Mangen MJJ, Salo H, Melliez H, Edmunds WJ, Yazdan Y, Beutels P. The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine 2009; 27:6121-8. [PMID: 19715781 DOI: 10.1016/j.vaccine.2009.08.030] [Citation(s) in RCA: 66] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2009] [Revised: 07/24/2009] [Accepted: 08/07/2009] [Indexed: 10/20/2022]
Abstract
Cost-effectiveness analyses are usually not directly comparable between countries because of differences in analytical and modelling assumptions. We investigated the cost-effectiveness of rotavirus vaccination in five European Union countries (Belgium, England and Wales, Finland, France and the Netherlands) using a single model, burden of disease estimates supplied by national public health agencies and a subset of common assumptions. Under base case assumptions (vaccination with Rotarix, 3% discount rate, health care provider perspective, no herd immunity and quality of life of one caregiver affected by a rotavirus episode) and a cost-effectiveness threshold of euro30,000, vaccination is likely to be cost effective in Finland only. However, single changes to assumptions may make it cost effective in Belgium and the Netherlands. The estimated threshold price per dose for Rotarix (excluding administration costs) to be cost effective was euro41 in Belgium, euro28 in England and Wales, euro51 in Finland, euro36 in France and euro46 in the Netherlands.
Collapse
Affiliation(s)
- Mark Jit
- Health Economics Unit, University of Birmingham, United Kingdom.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Lescure FX, Canestri A, Melliez H, Jauréguiberry S, Develoux M, Dorent R, Guiard-Schmid JB, Bonnard P, Ajana F, Rolla V, Carlier Y, Gay F, Elghouzzi MH, Danis M, Pialoux G. Chagas disease, France. Emerg Infect Dis 2008; 14:644-6. [PMID: 18394284 PMCID: PMC2570909 DOI: 10.3201/eid1404.070489] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Chagas Disease, France Chagas disease (CD) is endemic to Latin America; its prevalence is highest in Bolivia. CD is sometimes seen in the United States and Canada among migrants from Latin America, whereas it is rare in Europe. We report 9 cases of imported CD in France from 2004 to 2006.
Collapse
|
30
|
Pukenyte E, Nguyen S, Le Berre R, Faure K, Viget N, Melliez H, Mira JP, Guery B, Yazdanpanah Y. Pneumonie à Pasteurella multocida compliquée de choc septique chez un patient non immunodéprimé. Med Mal Infect 2007; 37:354-6. [PMID: 17303362 DOI: 10.1016/j.medmal.2006.05.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2005] [Accepted: 05/25/2006] [Indexed: 11/15/2022]
Abstract
Pneumonia with septicemia caused by Pasteurella multocida was diagnosed in an immunocompetent patient exposed to a dog. This case is remarkable by two aspects: first the absence of visible cutaneous lesion, and second the localization and severity of the infection caused by P. multocida even though the patient was immunocompetent. P. multocida can cause respiratory and systemic infection, and it is a possible diagnosis in case of exposure to animals, even without history of bite or scratch. Furthermore, severe infections caused by this pathogen can occur in immunocompetent patients, so that the implication of specific host factors in the severity of the disease can be suspected. Genetic features could be one of these.
Collapse
Affiliation(s)
- E Pukenyte
- Service universitaire des maladies infectieuses et du voyageur, centre hospitalier de Tourcoing, 59208 Tourcoing, France
| | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Tone A, Viget N, Choisy P, Baclet V, Ajana F, Gerard Y, Melliez H, Mouton Y, Yazdanpanah Y. P652 Incidence, reasons, and risk factors for hospital admissions in patients starting their clinical management in the era of combination antiretroviral therapy. Int J Antimicrob Agents 2007. [DOI: 10.1016/s0924-8579(07)70493-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
32
|
Melliez H, Boelle PY, Baron S, Mouton Y, Yazdanpanah Y. Effectiveness of childhood vaccination against rotavirus in sub-Saharan Africa: The case of Nigeria. Vaccine 2007; 25:298-305. [PMID: 17055130 DOI: 10.1016/j.vaccine.2006.07.038] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2006] [Revised: 06/10/2006] [Accepted: 07/20/2006] [Indexed: 10/24/2022]
Abstract
Rotavirus diarrhoea is associated with high childhood mortality in developing countries. A new vaccine was recently licensed in Mexico. The objective of this study was to assess the effectiveness of routine childhood vaccination by this new vaccine in a developing country. We constructed a decision tree to compare two alternatives: "no vaccination programme" and "vaccination programme". The estimates used for disease incidence, vaccine efficacy and coverage rates were derived from published data. We followed a hypothetical Nigerian cohort from birth to age five. The vaccine programme would prevent 284,000 cases of rotavirus diarrhoea annually and 6129 deaths due to the disease. In this study in a sub-Saharan country, we showed that rotavirus vaccination with a new vaccine substantially reduces the number of deaths from rotavirus diarrhoea and may be of great use in developing countries.
Collapse
Affiliation(s)
- H Melliez
- Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, France.
| | | | | | | | | |
Collapse
|
33
|
Senneville E, Melliez H, Beltrand E, Legout L, Valette M, Cazaubiel M, Cordonnier M, Caillaux M, Yazdanpanah Y, Mouton Y. Reply to Tattevin et al. Clin Infect Dis 2006. [DOI: 10.1086/504088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
34
|
Gérard Y, Melliez H, Mouton Y, Yazdanpanah Y. [Mitochondrial cytopathies associated with HIV infection]. Rev Neurol (Paris) 2006; 162:62-70. [PMID: 16446624 DOI: 10.1016/s0035-3787(06)74983-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
The tremendous progress achieved during the last few years with the use of highly active antiretroviral therapy in suppressing HIV replication together with improvements in immunity have been tempered by a growing number of new adverse effects. Mitochondrial toxicity is one aspect of these long-term toxicities of antiretroviral drugs, with the role of nucleoside analogs particularly underlined. Some cases of impaired mitochondrial function have been clearly identified, such as pancreatitis due to didanosine, neuropathy due to zalcitabine, myopathy due to zidovudine, and lactic acidosis due to stavudine. These mitochondrial toxicities can affect several organs, presenting different patterns of symptoms: from asymptomatic to states with few symptoms despite huge metabolic abnormalities whose prognosis is immediately life-threatening. Beyond the inhibition of DNA polymerase gamma using nucleoside analogs, responsible for decreasing mitochondrial DNA in certain targeted organs, it appears that several physiopathologic mechanisms interact to explain this observed toxicity, HIV itself plays a role, and the underlying genetic pool needs to be better identified. Such cases mean that, it is imperative to avoid cumulated toxicities caused by associated treatments. With serious cases, or persistent symptoms despite discontinuing the nucleoside analogs responsible for such toxicity, one must propose vitamins, mitochondrial co-factors, or anti-oxidants. However, the future lies in the use of potent, less toxic nucleoside analogs, and in developing compounds belonging to other classes of antiretrovirals.
Collapse
Affiliation(s)
- Y Gérard
- Service de Maladies Infectieuses, Hôpital Dron, Tourcoing.
| | | | | | | |
Collapse
|
35
|
Senneville E, Melliez H, Beltrand E, Legout L, Valette M, Cazaubiel M, Cordonnier M, Caillaux M, Yazdanpanah Y, Mouton Y. Culture of Percutaneous Bone Biopsy Specimens For Diagnosis of Diabetic Foot Osteomyelitis: Concordance With Ulcer Swab Cultures. Clin Infect Dis 2006; 42:57-62. [PMID: 16323092 DOI: 10.1086/498112] [Citation(s) in RCA: 187] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2005] [Accepted: 08/07/2005] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND We assessed the diagnostic value of swab cultures by comparing them with corresponding cultures of percutaneous bone biopsy specimens for patients with diabetic foot osteomyelitis. METHODS The medical charts of patients with foot osteomyelitis who underwent a surgical percutaneous bone biopsy between January 1996 and June 2004 in a single diabetic foot clinic were reviewed. Seventy-six patients with 81 episodes of foot osteomyelitis who had positive results of culture of bone biopsy specimens and who had received no antibiotic therapy for at least 4 weeks before biopsy constituted the study population. RESULTS Pathogens isolated from bone samples were predominantly staphylococci (52%) and gram-negative bacilli (18.4%). The distributions of microorganisms in bone and swab cultures were similar, except for coagulase-negative staphylococci, which were more prevalent in bone samples (P < .001). The results for cultures of concomitant foot ulcer swabs were available for 69 of 76 patients. The results of bone and swab cultures were identical for 12 (17.4%) of 69 patients, and bone bacteria were isolated from the corresponding swab culture in 21 (30.4%) of 69 patients. The concordance between the results of cultures of swab and of bone biopsy specimens was 42.8% for Staphylococcus aureus, 28.5% for gram-negative bacilli, and 25.8% for streptococci. The overall concordance for all isolates was 22.5%. No adverse events--such as worsening peripheral vascular disease, fracture, or biopsy-induced bone infection--were observed, but 1 patient experienced an episode of acute Charcot osteoarthropathy 4 weeks after bone biopsy was performed. CONCLUSIONS These results suggest that superficial swab cultures do not reliably identify bone bacteria. Percutaneous bone biopsy seems to be safe for patients with diabetic foot osteomyelitis.
Collapse
|
36
|
Pasquier F, Croxo C, Melliez H, Porte H, Bourgeois-Petit E, Cambier N, Rose C. [A possible complication of sickle-cell disease: pulmonary aspergillosis]. Rev Med Interne 2005; 27:260-3. [PMID: 16364507 DOI: 10.1016/j.revmed.2005.10.024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2005] [Accepted: 10/19/2005] [Indexed: 11/20/2022]
|
37
|
Melliez H, Boelle PY, Baron S, Mouton Y, Yazdanpanah Y. [Morbidity and cost of rotavirus infections in France]. Med Mal Infect 2005; 35:492-9. [PMID: 16316731 DOI: 10.1016/j.medmal.2005.08.007] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2005] [Accepted: 08/31/2005] [Indexed: 10/25/2022]
Abstract
BACKGROUND Rotavirus is the most common cause of severe diarrhea in children. Morbidity and mortality related to rotavirus infection is not well known in temperate countries in general, and in France in particular. OBJECTIVES The aim of this study was estimate the morbidity, mortality, and cost related to the rotavirus infection in France, in order to assess the potential impact of a vaccination program. METHODS A birth cohort was followed until 5 years of age using a decision tree model. Rotavirus infection incidence rates were modeled according to age, seasons, and breast-feeding status. RESULTS Based on estimates from a decision model, we found that in France, rotavirus infection was responsible for 300,000 annual episodes of acute diarrhea, 138,000 visits to general practitioners, 18,000 hospitalizations, and 9 deaths. The annual direct cost related to rotavirus infection care was estimated at 28 million euros. CONCLUSION This study demonstrates the high morbidity and cost of care associated with rotavirus infection in France. The decision tree model developed in this study could be used in the future to estimate the potential effectiveness, cost and cost-effectiveness of childhood vaccination strategies using new rotavirus vaccines.
Collapse
Affiliation(s)
- H Melliez
- Service universitaire régional de maladies infectieuses, faculté de médecine de Lille, 135, rue du Président-Coty, BP 619, 59208 Tourcoing cedex, France.
| | | | | | | | | |
Collapse
|
38
|
Seddik M, Melliez H, Seguy D, Viget N, Cortot A, Colombel JF. Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflamm Bowel Dis 2005; 11:618-20. [PMID: 15905713 DOI: 10.1097/01.mib.0000164002.32735.c2] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
39
|
Melliez H, Hachulla E, Hatron P, Lambert M, Queyrel V, Michon-Pasturel U, Devulder B. Tolérance et efficacité du Remicade® dans les maladies systémiques. Rev Med Interne 2002. [DOI: 10.1016/s0248-8663(02)80440-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
40
|
Devaux JP, Andrieux S, Melliez H, Copin MC, Azar R. [Type 1 membranoproliferative glomerulonephritis in a patient with acquired partial lipodystrophy]. Presse Med 2001; 30:790-1. [PMID: 11388149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/20/2023] Open
|
41
|
Delcey V, Queyrel V, Michon-Pasturel U, Melliez H, Lambert M, Hachulla E, Hatron P, Devulder B. Infections à cytomégalovirus survenant au cours d'un lupus systémique et d'une micropolyangéite. Rev Med Interne 2000. [DOI: 10.1016/s0248-8663(00)90133-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Azar R, Lionet A, Melliez H, Verove C, de Lattre C. [A case of septicemia manifesting as a black esophagus]. Presse Med 1999; 28:1517. [PMID: 10526556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/14/2023] Open
|